Last reviewed · How we verify

ketorolac + bupivacaine — Competitive Intelligence Brief

ketorolac + bupivacaine (ketorolac + bupivacaine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID + local anesthetic combination. Area: Pain Management / Anesthesia.

marketed NSAID + local anesthetic combination COX-1/COX-2 (ketorolac); voltage-gated sodium channels (bupivacaine) Pain Management / Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

ketorolac + bupivacaine (ketorolac + bupivacaine) — The Hospital for Sick Children. Ketorolac inhibits prostaglandin synthesis via COX inhibition to reduce pain and inflammation, while bupivacaine blocks sodium channels in nerve membranes to provide local anesthesia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ketorolac + bupivacaine TARGET ketorolac + bupivacaine The Hospital for Sick Children marketed NSAID + local anesthetic combination COX-1/COX-2 (ketorolac); voltage-gated sodium channels (bupivacaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID + local anesthetic combination class)

  1. The Hospital for Sick Children · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ketorolac + bupivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/ketorolac-bupivacaine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: